Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025
Intra-Cellular Therapies Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Intra-Cellular Therapies stock had an average target of 106.75, with a low estimate of 74 and a high estimate of 132.
Price Target: $106.75 (-19.05%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 2, 2025.
Analyst Ratings
The average analyst rating for Intra-Cellular Therapies stock from 13 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 2 | 2 | 2 |
| Buy | 5 | 5 | 4 | 4 | 4 | 3 |
| Hold | 2 | 2 | 6 | 7 | 7 | 8 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Reiterates $132 | Hold | Reiterates | $132 | +0.10% | Apr 2, 2025 |
| Mizuho | Mizuho | Buy → Hold Downgrades $140 → $132 | Buy → Hold | Downgrades | $140 → $132 | +0.10% | Feb 24, 2025 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Feb 21, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $119 → $132 | Strong Buy → Hold | Downgrades | $119 → $132 | +0.10% | Jan 31, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $108 → $132 | Buy → Hold | Downgrades | $108 → $132 | +0.10% | Jan 22, 2025 |
Financial Forecast
Revenue This Year
966.26M
from 680.85M
Increased by 41.92%
Revenue Next Year
1.57B
from 966.26M
Increased by 62.07%
EPS This Year
0.20
from -0.72
EPS Next Year
4.03
from 0.20
Increased by 1,917.44%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.8B | |||
| Avg | 966.3M | 1.6B | |||
| Low | 877.5M | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 57.4% | 81.2% | |||
| Avg | 41.9% | 62.1% | |||
| Low | 28.9% | 50.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.33 | 5.63 | |||
| Avg | 0.20 | 4.03 | |||
| Low | -0.50 | 1.95 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 2,719.3% | |||
| Avg | - | 1,917.4% | |||
| Low | - | 876.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.